Insider Selling: MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Sells 55,410 Shares of Stock

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Erez Aminov sold 55,410 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $1.39, for a total value of $77,019.90. Following the sale, the chief executive officer now directly owns 1,105,790 shares of the company’s stock, valued at approximately $1,537,048.10. This represents a 4.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MIRA Pharmaceuticals Trading Up 1.6 %

Shares of MIRA stock opened at $1.29 on Friday. The company has a market cap of $21.36 million, a price-to-earnings ratio of -2.30 and a beta of 3.09. The stock has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.33. MIRA Pharmaceuticals, Inc. has a 12-month low of $0.51 and a 12-month high of $5.01.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. On average, equities analysts forecast that MIRA Pharmaceuticals, Inc. will post -0.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on MIRA shares. Rodman & Renshaw started coverage on MIRA Pharmaceuticals in a research note on Monday, September 30th. They set a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW raised MIRA Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Finally, Ascendiant Capital Markets started coverage on MIRA Pharmaceuticals in a research note on Monday, August 5th. They set a “buy” rating and a $11.00 target price for the company.

Institutional Investors Weigh In On MIRA Pharmaceuticals

An institutional investor recently raised its position in MIRA Pharmaceuticals stock. Virtu Financial LLC increased its position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 330.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,055 shares of the company’s stock after acquiring an additional 48,397 shares during the period. Virtu Financial LLC owned approximately 0.43% of MIRA Pharmaceuticals worth $69,000 as of its most recent SEC filing. 35.16% of the stock is currently owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.